Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso

摘要

There is provided an antagonist of IL-23 and of IL-17A or IL-17F comprising: (i) an antibody or antibody fragment that binds the p19 subunit of IL-23 as shown in SEQ ID NO: 4; and (ii) an antibody or antibody fragment that binds IL-17A as shown in SEQ ID NO: 2 or that binds IL-17F as shown in SEQ ID NO: 6; wherein the antibody or antibody fragment that binds IL-17A or IL-17F comprises a HCDR1 amino acid sequence, a HCDR2 amino acid sequence, and a HCDR3 amino acid sequence of the variable heavy region selected from the group consisting of the variable heavy region of the hybridoma of ATCC Patent Deposit Designation PTA-7988; and wherein the variable light region comprises a LCDR1 amino acid sequence, a LCDR2 amino acid sequence, and a LCDR3 amino acid sequence of the variable light region of the hybridoma of ATCC Patent Deposit Designation PTA-7988.